Literature DB >> 21910727

Lung transplantation affects expression of the chemokine receptor type 4 on specific T cell subsets.

A W M Paantjens1, E A van de Graaf, J M Kwakkel-van Erp, T Hoefnagel, D A van Kessel, J M M van den Bosch, H G Otten.   

Abstract

Alloreactive T cells that infiltrate the graft after lung transplantation (LTx) play a role in chronic rejection. Chemokines such as thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and monocyte chemotactic protein-1 (MCP-1) are produced locally in the lung and attract T cells via chemokine receptor 4 (CCR4). In a TARC gradient, cells expressing CCR4(++) migrate more efficiently than CCR4(+) -expressing cells. In this study, we compared the CCR4 expression of T cells in blood from 20 lung transplant recipients to healthy controls. We then examined whether CCR4 expression is associated with the occurrence of chronic rejection. The CCR4(++) expression was decreased on CD4 T cells from LTx patients (P < 0·0001) when compared to healthy controls. The analysis of CD4 T cell subsets showed that this decrease was present on central memory, effector memory and terminally differentiated T cells (P = 0·0007, P < 0·0001 and P = 0·05, respectively), while a trend was found for naive CD4 T cells (P = 0·06). Also, the expression of CCR4(+) on regulatory T cells (T(regs) ) was decreased in LTx patients when compared to healthy controls (P = 0·02). Interestingly, the CCR4(++) expression on CD4 effector memory T cells was decreased in patients developing chronic rejection sometimes more than a year before the clinical diagnosis when compared to patients who did not (P = 0·04). The analysis of CD8 T cell subsets only showed the CCR4(+) expression to be increased significantly on effector memory and terminally differentiated CD8 T cells (P = 0·02, P = 0·03, respectively) in LTx patients, but no relation was found in chronic rejection. In conclusion, the expression of CCR4 on T cell subsets was altered after LTx and appears to be related to chronic rejection.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910727      PMCID: PMC3193925          DOI: 10.1111/j.1365-2249.2011.04450.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis.

Authors:  Johanna M Kwakkel-van Erp; Inge M Haeck; Annelieke W M Paantjens; Ed A van de Graaf; Walter G J van Ginkel; Mirjam J Knol; Marjolein S de Bruin-Weller; Jan-Willem J Lammers; Edward F Knol; Carla Bruijnzeel-Koomen; Henny G Otten
Journal:  J Am Acad Dermatol       Date:  2010-09       Impact factor: 11.527

2.  Lung transplantation under a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen results in low titers of HLA and MICA IgG antibodies which are not related to development of BOS.

Authors:  Annelieke W M Paantjens; Ed A van de Graaf; Walter G J van Ginkel; Jules M M van den Bosch; Henny G Otten
Journal:  J Heart Lung Transplant       Date:  2010-03-05       Impact factor: 10.247

3.  CC chemokine receptor 4 contributes to innate NK and chronic stage T helper cell recall responses during Mycobacterium bovis infection.

Authors:  Valerie R Stolberg; Bo-Chin Chiu; Brian M Schmidt; Steven L Kunkel; Matyas Sandor; Stephen W Chensue
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

4.  Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome.

Authors:  Sangeeta M Bhorade; Hong Chen; Luciana Molinero; Chuanhong Liao; Edward R Garrity; Wickii T Vigneswaran; Rebecca Shilling; Anne Sperling; Anita Chong; Maria-Luisa Alegre
Journal:  Transplantation       Date:  2010-09-15       Impact factor: 4.939

5.  Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.

Authors:  Aric L Gregson; Aki Hoji; Vyacheslav Palchevskiy; Scott Hu; S Samuel Weigt; Eileen Liao; Ariss Derhovanessian; Rajeev Saggar; Sophie Song; Robert Elashoff; Otto O Yang; John A Belperio
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

6.  Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome.

Authors:  A W M Paantjens; J M Kwakkel-van Erp; W G J van Ginkel; D A van Kessel; J M M van den Bosch; E A van de Graaf; H G Otten
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

7.  Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation.

Authors:  Anjali S Golocheikine; Deepti Saini; Sabarinathan Ramachandran; Elbert P Trulock; Alexander Patterson; T Mohanakumar
Journal:  Transpl Immunol       Date:  2007-09-11       Impact factor: 1.708

8.  Chemokine redundancy in BOS pathogenesis. A possible role also for the CC chemokines: MIP3-beta, MIP3-alpha, MDC and their specific receptors.

Authors:  F Meloni; N Solari; S Miserere; M Morosini; A Cascina; C Klersy; E Arbustini; C Pellegrini; M Viganò; A M Fietta
Journal:  Transpl Immunol       Date:  2007-09-05       Impact factor: 1.708

9.  Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients.

Authors:  Pandurangan Vijayanand; Kesta Durkin; Guido Hartmann; Jaymin Morjaria; Gregory Seumois; Karl J Staples; David Hall; Christina Bessant; Michelle Bartholomew; Peter H Howarth; Peter S Friedmann; Ratko Djukanovic
Journal:  J Immunol       Date:  2010-03-17       Impact factor: 5.422

10.  Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.

Authors:  Yurika Yogo; Seitaro Fujishima; Takashi Inoue; Fumitake Saito; Takayuki Shiomi; Kazuhiro Yamaguchi; Akitoshi Ishizaka
Journal:  Respir Res       Date:  2009-08-29
View more
  3 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

2.  Increase of Th17 Cell Phenotype in Kidney Transplant Recipients with Chronic Allograft Dysfunction.

Authors:  Byung Ha Chung; Kyoung Woon Kim; Bo-Mi Kim; Kyoung Chan Doh; Mi-La Cho; Chul Woo Yang
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

3.  Clinical significance of CCR7+CD8+ T cells in kidney transplant recipients with allograft rejection.

Authors:  Kyoung Woon Kim; Bo-Mi Kim; Kyoung Chan Doh; Mi-La Cho; Chul Woo Yang; Byung Ha Chung
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.